SlideShare ist ein Scribd-Unternehmen logo
1 von 8
Downloaden Sie, um offline zu lesen
BIOTECH’S MOST RESPECTED NEWS SOURCE FOR OVER 17 YEARS




WEDNESDAY                                                                                                                        VOLUME 20, NO. 169
SEPTEMBER 2, 2009                                                                                                                        PAGE 1 OF 7

Celgene Likes PTC’s GEMS, Too                                                   FDA Panel: More Clolar Data
PTC Gets $12M Up Front in                                                       Needed for Approval in AML
Roche Deal Worth up to $1.9B
                                                                                By Donna Young
By Trista Morrison                                                              Washington Editor
Staff Writer                                                                         SILVER SPRING Md. – An FDA advisory panel Tuesday
    PTC Therapeutics Inc. is expected to announce two                           said more data were needed to validate the efficacy and
drug discovery deals on Wednesday, a potential $1.9 billion                     safety of drugs from Genzyme Corp. and Vion Pharmaceu-
whopper with Roche AG and an option exercise by Celgene                         ticals Inc. to treat elderly patients with acute myeloid
Corp. for which terms were not disclosed.                                       leukemia (AML), stating that the firms’ single-arm Phase II
    Both deals center on PTC’s Gene Expression Modula-                          studies were insufficient on which to base approval.
tion by Small-molecules (GEMS) technology platform,                                  Shares of Genzyme (NASDAQ:GENZ) closed at $55.39,
which identifies small molecules that regulate post-tran-                       down 32 cents, while shares of Vion (OTC BB:VION)
scriptional control mechanisms.                                                 plunged 23 percent, or 77 cents, to close at $2.60.
    In the Roche deal, PTC will get $12 million up front as                          In a 9-to-3 vote, the FDA Oncologic Drugs Advisory
well as research funding to find small molecules that hit                       Committee (ODAC) said Genzyme should be required to
four jointly selected central nervous system disease tar-                       conduct a randomized controlled trial before regulators
gets. Each target could eventually bring up to $239 million                     consider approving Clolar (clofarabine) as a first-line treat-
in research, development, regulatory and commercial                             ment for adults 60 years or older with AML with at least
                                           See PTC, Page 3                                                                 See FDA, Page 4


One Down, One Left: Acadia’s                                                    Pain Deal Still in Place
Pimavanserin Fails in Phase III                                                 Icagen’s Phase II Asthma Win:
By Jennifer Boggs
                                                                                Added Lure for Pfizer Buyout?
Assistant Managing Editor                                                       By Randy Osborne
    Any expectations raised in May when Acadia Pharma-                          Staff Writer
ceuticals Inc. impressed investors with a potentially lucra-                         Partner-forsaken Icagen Inc.’s upward stock ride on
tive North American partnership for Phase III-stage pima-                       top-line Phase IIa news in allergic asthma with senicapoc
vanserin were dashed when the drug failed to hit its pri-                       gives the firm a leg up during its ongoing exploration of
mary endpoint in the first of two pivotal studies in Parkin-                    strategic alternatives, and just might lure pain collaborator
son’s disease psychosis.                                                        Pfizer Inc. to the table for takeover talks.
    News sent the San Diego-based firm’s stock (NASDAQ:                              “I wouldn’t rule that out as a possibility,” said Richard
ACAD), which had run up in the weeks ahead of the data,                         D. Katz, chief financial officer of Research Triangle Park,
plunging 66 percent, or $3.84, to close Tuesday at $2.                          N.C.-based Icagen.
    Top-line data from the six-week, 298-patient trial                               Research funding for pain research from Pfizer (soon
showed improvements in both treatment arms, according                           to merge with Wyeth, of Madison, N.J.) was slated to end
the Scale for the Assessment of Positive Symptoms, but                          this month, but the deal was extended for six weeks, Katz
Acadia said a higher-than-expected response in the                              said.
placebo arm prevented the study from meeting statistical                             “We’re in the process of discussing with them a
                                        See Acadia, Page 5                                                                 See Icagen, Page 6




INSIDE:             NOVAVAX TURNS TO FUNDING AS VLP VACCINE PASSES MIDSTAGE..............2
                    CLINIC ROUNDUP ..........................................................................................3

             To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                   Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, SEPTEMBER 2, 2009                                     BIOWORLD® TODAY                                                             PAGE 2 OF 7

Second Phase II Trial Positive                                                strains targeted for the 2008-2009 flu season, Singhvi
Novavax Will Need More Cash                                                   explained. Novavax has now shown that the VLP vaccine
                                                                              candidate could work in different formulations, he said.
to Push VLP Vaccine Farther                                                        Novavax hopes that its vaccine candidate, which is
By Catherine Hollingsworth                                                    made in cell cultures, will stand apart from those that are
Staff Writer                                                                  made in egg cultures, which can have a lengthy cultivation
      Novavax reported positive results from a second Phase                   period. Novavax’s vaccine candidate has the potential to be
II trial of its trivalent seasonal influenza virus-like particle              made faster for annual flu season.
(VLP) vaccine candidate.                                                           Another distinction is that Novavax’s VLP vaccine can-
      The Rockville, Md.-based company has a Spain-based                      didate includes three viral proteins important for inducing
partner, ROVI Pharmaceutical Laboratories SA, that is help-                   a broad immune response: two surface proteins, hemag-
ing to fund the VLP vaccine studies through Phase III and                     glutinin (HA) and neuraminidase (NA), and a core matrix
ultimately toward an anticipated regulatory approval in                       protein, M1. Most seasonal vaccines consist almost entirely
Europe.                                                                       of HA with little or no NA and M1 , according to the com-
      But the company will need additional funding to satisfy                 pany’s website.
FDA requirements, Rahul Singhvi, president and CEO of                              The HA protein induces an antibody that neutralizes or
Novavax, told BioWorld Today.                                                 blocks the growth of the virus; NA induces antibodies that
      In the U.S., Novavax has said that it is seeking support                prevent cell-to-cell transmission of virus down the respira-
from the Health and Human Services Department’s Bio-                          tory tract, potentially reducing the severity of influenza
medical Advanced Research and Development Authority.                          disease; and cell-mediated immune responses to M1 may
The company also is considering a potential partner as it                     lead to destruction of cells already infected.
seeks U.S. approval of the VLP product, Singhvi indicated.                         VLPs are recombinant structures that mimic the size
      In its most recent earnings report, Novavax reported                    and shape of a virus. They are incapable of replication but
that it had close to $38 million in cash and no long-term                     can induce potent immune response, the company said.
debt on its balance sheet.                                                         Rodman & Renshaw analyst Elemer Piros wrote in a
      The latest Phase II study of 221 patients showed that                   research note that “Novavax’s VLP vaccine technology is
the VLP-based vaccine was well tolerated and induced                          truly revolutionary compared to the traditional egg-based
robust immune responses against the three influenza                           vaccines.”
strains (H3N2, H1N1 and B). The three strains were matched                         He added that the company’s developing seasonal vac-
to the strains recommended for influenza vaccines during                      cine business “may be overlooked,” noting that it is apply-
the past flu season, 2008-2009.                                               ing its technology toward developing vaccines for respira-
      The positive outcome of the second Phase II study sup-                  tory syncytial virus, shingles, HIV, and severe acute respira-
ported moving ahead with larger head-to-head trials of VLP                    tory syndrome as well as pandemic H1N1 vaccine.
and egg-based vaccines, the first of which is scheduled to                         Its VLP-based vaccine against the H1N1 flu vaccine is
start this fall in elderly adults, Novavax said. Phase III stud-              advancing into preclinical development and could enter the
ies are expected next year.                                                   clinic later this year. The company’s drug candidate for RSV
      The previous Phase II study also was positive. While the                also is expected to be in the clinic next year, Singhvi said.
first Phase II study involved a 2005-2006 formulation, the                         Shares in the Rockville, Md.-based company (NASDAQ:
second study showed that the product worked against                           NVAX) rose 61 cents, to close at $6.65 Tuesday. ■

                                                                                                               SUBSCRIBER INFORMATION
   BioWorld® Today (ISSN# 1541-0595) is published every business day by AHC Media LLC, 3525 Piedmont
   Road, Building Six, Suite 400, Atlanta, GA 30305 U.S.A. Opinions expressed are not necessarily those        Please call (800) 688-2421 to subscribe
   of this publication. Mention of products or services does not constitute endorsement. BioWorld® and         or if you have fax transmission problems.
   BioWorld® Today are trademarks of AHC Media LLC, a Thompson Publishing Group company. Copyright             Outside U.S. and Canada, call (404)
   © 2009 AHC Media LLC. All Rights Reserved. No part of this publication may be reproduced without the        262-5476. Our customer service hours
   written consent of AHC Media LLC. (GST Registration Number R128870672).                                     are 8:30 a.m. to 6:00 p.m. EST.
                                                                                                               Glen Harris, (404) 262-5408
   ATLANTA NEWSROOM: Managing Editor: Glen Harris. Assistant Managing Editor: Jennifer Boggs.
                                                                                                               Jennifer Boggs, (404) 262-5427
                           Senior Staff Writer: Karen Pihl-Carey. Senior Production Editor: Ann Duncan.
                                                                                                               Anette Breindl, (518) 595-4041
                           Staff Writer: Randy Osborne.
                                                                                                               Trista Morrison, (858) 901-4785
   WASHINGTON BUREAU: Washington Editor: Donna Young. Staff Writer: Catherine Hollingsworth.                   Donna Young, (202) 739-9556
   WEST COAST BUREAU: Staff Writer: Trista Morrison.                                                           Catherine Hollingsworth, (301) 576-0667
   EAST COAST BUREAU: Science Editor: Anette Breindl.                                                          Senior Vice President/Group Publisher:
   BUSINESS OFFICE:        Senior Vice President/Group Publisher: Donald R. Johnston.                          Donald R. Johnston, (404) 262-5439
                           Senior Marketing Product Manager: Chris Walker.                                     Internet: http://www.bioworld.com
                           Marketing Coordinator: Sonia Blanco.
                           Account Representatives: Bob Sobel, Randee Papush.
   DISPLAY ADVERTISING: For ad rates and information, please call Stephen Vance at (404) 262-5511
                           or email him at stephen.vance@ahcmedia.com.
   REPRINTS:               For photocopy rights or reprints, call our reprints department at (404) 262-5479.
   PRESS MATERIALS:        Send all press releases and related information to newsdesk@bioworld.com.
WEDNESDAY, SEPTEMBER 2, 2009                                   BIOWORLD® TODAY                                                            PAGE 3 OF 7

PTC                                                                          trophy and a pivotal Phase III trial for cystic fibrosis. A
Continued from page 1                                                        proof-of-concept trial in hemophilia also is under way, and
milestone payments, plus double-digit royalties, and Roche                   Peltz said PTC is “just nailing down” a fourth program,
has an option to add four more targets under the same                        which likely will focus on a metabolic disorder. PTC inked a
terms.                                                                       $437 million partnership with Genzyme Corp. on the drug
     All-told that’s $1.9 billion in potential milestones. PTC’s             last year but retained U.S. and Canadian rights. (See
senior vice president of corporate development, Cláudia                      BioWorld Today, July 18, 2008.)
Hirawat, noted that the payments are spread across the                            Moving forward, “we think this is going to be a pretty
development and commercialization continuum with no                          exciting next couple of years,” Peltz said.
particular emphasis on the front or back end.                                     In a time when many biotechs are struggling and
     Concurrent with the new Roche deal, PTC announced                       experts claim you can’t build a fully integrated pharmaceu-
that Celgene exercised its option to partner on a GEMS                       tical company, PTC is well funded and moving the first of its
oncology target. Two years ago, Celgene made a $20 mil-                      internally discovered candidates toward the commercial
lion equity investment in PTC in exchange for options on                     realm. ■
two targets, and the exercise of one of them will trigger an
undisclosed stream of discovery, development, regulatory
and commercial milestone payments as well as royalties.
(See BioWorld Today, Sept. 14, 2007.)
                                                                                       C    L I N I C            RO       U N D U P
     Roche and Celgene are only the latest to notice the
sparkle of PTC’s GEMS. The company previously inked a                              • Ablynx NV, of Ghent Belgium, has begun a Phase II
$212 million hepatitis C deal with Schering-Plough Corp., a                  study for its antithrombotic Nanobody ALX-0081 , a first-in-
$345 million cardiovascular deal with CV Therapeutics Inc.                   class nanobody targeting von Willebrand Factor. The open-
(now part of Gilead Sciences Inc.) and a $1.2 billion deal                   label, randomized study is designed to evaluate the safety
with Pfizer Inc. (See BioWorld Today, March 21 , 2006, June                  and efficacy of multiple doses of ALX-0081 vs. the GPIIb/IIIa
13, 2006, and Jan. 9, 2007.)                                                 inhibitor ReoPro in patients undergoing percutaneous
     Stuart Peltz, president and CEO of PTC, explained that                  coronary intervention. Patients with unstable angina or
the attraction of GEMS lies in its ability to provide control                patients with stable angina with at least two factors indi-
over difficult, intractable or uncharacterized protein tar-                  cating high risk will be included in the study.
gets.                                                                              • Antisoma plc, of London, said the ATTRACT-1 Phase
     While the middle of an RNA molecule serves as a blue-                   III trial of its tumor vasculature disrupting agent ASA404 in
print for making proteins, the untranslated ends of the                      non-small-cell lung cancer (NSCLC) has reached its enroll-
molecule determine how much protein gets made. By                            ment target of 1 ,200 patients. The trial is the single pivotal
focusing on the untranslated ends, PTC’s GEMS platform                       registration study for the drug as a first-line treatment for
churns out drugs that can increase or decrease the amount                    squamous and nonsquamous NSCLC, and is being con-
of protein produced. In addition to providing a new                          ducted by Novartis AG, of Basel, Switzerland, Antisoma’s
approach to tough targets, GEMS can be used to replace                       development and commercialization partner for ASA404.
temperamental biologics with convenient small molecules,                     The company expects results will be available in time to
Peltz said.                                                                  support potential marketing applications in 201 1.
     PTC has its own GEMS molecule, PTC299, moving                                 • Kowa Co. Ltd., of Tokyo, presented data showing
through Phase II trials for breast cancer, solid tumors,                     that pitavastatin is noninferior to atorvastatin and simvas-
Kaposi’s sarcoma associated with human immunodefi-                           tatin at usual therapeutic doses in patients with primary
ciency virus infection and brain tumors associated with                      hypercholesterolemia or combined dyslipidemia, as meas-
neurofibromatosis type 2.                                                    ured by reduction of low density lipoprotein cholesterol
     PTC299 targets vascular endothelial growth factor                       (LDL-C) from baseline. LDL-C target attainment data were
(VEGF), placing it into a crowded field that includes Avastin                similar when comparing pitavastatin to atorvastatin and
(bevacizumab, Genentech/Roche) and loads of experimen-                       simvastatin, although pitavastatin demonstrated signifi-
tal drugs, but Hirawat said PTC’s drug works “upstream of                    cantly higher LDL-C target attainment compared to sim-
what everyone else is doing” and thus far hasn’t elicited                    vastatin in the lower dose study-arm (pitavastatin 2 mg vs.
typical VEGF inhibitor side effects.                                         simvastatin 20 mg) (p = 0.047). Continued gradual
     Yet the crown jewel of PTC’s pipeline has nothing to do                 increases in high density lipoprotein cholesterol were
with GEMS. Ataluren (formerly PTC124) is based on PTC’s                      observed over the long-term, supported by data from a 52
nonsense suppression technology, which allows cellular                       week extension study. Pitavastatin also demonstrated a
machinery to read through nonsense mutations in genetic                      favorable safety and tolerability profile to 52 weeks. Data
disorders, resulting in production of a functional protein.                  were presented at the European Society of Cardiology
     Ataluren is in a pivotal Phase IIb trial for muscular dys-              meeting in Barcelona, Spain.

              To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                    Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, SEPTEMBER 2, 2009                                   BIOWORLD® TODAY                                                            PAGE 4 OF 7

FDA                                                                          ated approval was for a “fairly timely” completion of follow-
Continued from page 1                                                        up studies.
one unfavorable baseline prognostic factor.                                       Michael Vasconcelles, group vice president and global
     A larger ODAC panel in the afternoon voted 13 to 0 that                 therapeutic area head of transplant and oncology at Gen-
Vion also be required to conduct a randomized trial of                       zyme, said the early combination safety studies, which will
Onrigin (laromustine) to establish the safety and efficacy of                serve as the basis of the randomized Phase III pediatric
the drug as a single agent for remission induction in                        trial, were initiated “immediately after” the accelerated
patients 60 years or older with de novo, poor-risk AML.                      approval was granted and have been ongoing for the past
     AML, the most common type of acute leukemia, affects                    four years.
elderly adults very differently than younger patients with                        Mark Enyedy, head of oncology and multiple sclerosis
the disease. Elderly patients have higher risk factors and                   at Genzyme, told reporters after the meeting that the com-
have lower response rates, with shorter overall survival.                    pany has had a “strong track record” of fulfilling postap-
     Genzyme and Vion argued that their drugs would fill an                  proval commitments. “Genzyme is one of the companies in
unmet need for elderly patients, a population for which                      the industry that has completed those postapproval com-
two-thirds typically go untreated because of the poorer                      mitments,” he contended.
outcomes.                                                                         Genzyme submitted its supplemental application for
     In Genzyme’s CLO243 study, 51 of 1 12 patients, or 45.5                 AML in elderly patients to the FDA in November 2008 based
percent, achieved overall remission, defined as either com-                  on its single-arm Phase II CLO243 trial of Clolar in older adult
plete remission or complete remission with incomplete                        patients with previously untreated AML who were deemed
platelet recovery. Of the 51 responders, 38, or 74.5 percent,                unfit for conventional treatment with seven days of continu-
achieved OR after one cycle of Clolar and 13, or 25.5 per-                   ous infusion cytarabine plus three days of an anthracycline
cent, achieved OR after two cycles.                                          or anthracenedione, known as 7+3 induction chemotherapy.
     In Vion’s single-arm CLI-043 study, 27 of 85 patients, or                    The company also submitted data from a supportive
31.8 percent, achieved OR. In the company’s CLI-033 sup-                     multicenter, single-arm study, known as BIOV-121 , in a sim-
portive single-arm study, 38.2 percent of patients achieved                  ilar population.
OR. Across all 140 elderly de novo poor-risk AML patients in                      Mark Hayes, group vice president of regulatory affairs at
both studies, 34.3 percent achieved OR.                                      Genzyme, said the company had proposed a randomized
     Although the ODAC panelists agreed that the remission                   controlled trial and submitted a special protocol assessment
rates were impressive, they were unconvinced that the Gen-                   to the FDA for study CLO342 in March 2006 of Clolar in com-
zyme’s and Vion’s single-arm studies were sufficient to show                 bination with low-dose cytarabine vs. low-dose cytarabine
that the drugs’ benefits outweighed the risks or that it was                 alone in previously untreated older adults with AML.
clear that the medications were any better than chemotherapy.                     But, he said, a panel of outside AML experts who
     Richard Pazdur, director of the FDA’s Office of Oncol-                  reviewed the study protocol for Genzyme could not agree
ogy Drug Products, noted that the agency had urged both                      on an appropriate comparator arm for the proposed study
companies to conduct randomized controlled trials before                     population and recommended a single-arm, single-agent
submitting their applications – advice that went unheeded                    clinical study instead.
by Genzyme and Vion.                                                              But Pazdur noted that the FDA has heard similar argu-
     Clolar already is marketed in the U.S. The FDA in 2004                  ments before from drugmakers.
granted accelerated approval for the drug as treatment for                        “This is a common, common comment,” he said. Pazdur
pediatric patients with relapsed or refractory acute lym-                    argued that companies have several options for compara-
phoblastic leukemia after at least two prior regimens. The                   tor arms, including using investigational drugs.
company has a commitment to complete a Phase III study                            Genzyme currently has an ongoing Phase III random-
of the drug in pediatric patients to gain full approval in that              ized, double-blind, placebo-controlled study comparing
population.                                                                  Clolar plus intermediate-dose cytarabine vs. intermediate-
     Pazdur, however, appeared to lob a warning shot                         dose cytarabine alone in adult patients 55 years or older
across the bow by calling out the fact that the company has                  with relapsed or refractory AML after receiving up to two
yet to start that trial six years after the approval.                        prior induction regimens.
     Genzyme officials said the company is nearing com-                           But panelists noted that the population in that trial is
pletion of its Phase I/II development program of Clolar in                   very different in age and disease type as the population Gen-
combination with chemotherapy and plans to start the                         zyme is seeking approval for in its supplemental application.
Phase III randomized controlled trial in newly diagnosed                          Vion’s application primarily relies on the findings of a
children in 2010.                                                            single-arm study and a post-hoc subset of patients from a
     But panelist Thomas Fleming, a professor of biostatis-                  second single-arm study. The company also submitted data
tics at the University of Washington in Seattle, scolded Gen-                from a randomized controlled trial, which was placed on
zyme, asserting that the “congressional intent” of acceler-                  clinical hold due to excess death in the Onrigin arm. ■

              To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                    Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, SEPTEMBER 2, 2009                                   BIOWORLD® TODAY                                                            PAGE 5 OF 7

Acadia                                                                       Alzheimer’s disease psychosis, schizophrenia and insom-
Continued from page 1                                                        nia. The companies already selected ADP as the second
significance. Mean reductions in SAPS scores were 5.8                        indication to explore and “we’ll decide on a path forward
points in the 10-mg pimavanserin arm, 6.7 points in the 40-                  after we analyze the data” from the first PDP study, he
mg arm and 5.9 points in the placebo group.                                  added.
     The company plans further analysis, but executives                           Nevertheless, the first Phase III failure marked a set-
said they were at a loss to explain the high placebo                         back for the firm, which had been riding high since pleas-
response. While the drug missed the SAPS endpoint in an                      antly surprising analysts and investors with its potential
earlier Phase II study, “we got a very nice separation                       $395 million Biovail deal. That partnership, coming before
between the treatment and placebo [groups],” Acadia CEO                      the release of Phase III data, sent the company’s stock soar-
Uli Hacksell told BioWorld Today.                                            ing 134 percent and seemed to quell some of the doubt sur-
     During the firm’s conference call, executives said a pre-               rounding pimavanserin’s efficacy following mixed Phase II
vious four-week study had shown a change from baseline                       data. (See BioWorld Today, May 5, 2009.)
of only 1. 1 points in the placebo study, and investigators                       It also offered some reassurance for investors skeptical
were expecting a similar trend in the Phase III trial, which                 about the drug’s potential in the PDP market. There are no
was 90 percent powered for a 5-point difference between                      FDA-approved drugs specifically for PDP, but there are
treatment and placebo.                                                       generic atypical antipsychotics that are used off-label, with
     SAPS is the recommended endpoint to describe psy-                       limited efficacy. The most efficacious of those is clozapine,
chosis in Parkinson's disease, a condition involving halluci-                but it carries several well-known side effects.
nations and delusions that affects about 40 percent of the                        Acadia, which earned $30 million up front from Biovail
estimated 1.5 million U.S. patients with Parkinson’s, Hack-                  in its May licensing deal, had about $66.2 million in the
sell said.                                                                   bank as of June 30. The firm said it expects to end this year
     All patients enrolled in the study remained on their sta-               with more than $40 million, enough to carry it into the first
ble doses of dopamine drugs, and the study met its sec-                      half of 201 1.
ondary endpoint of motoric tolerability, as measured by the                       Beyond pimavanserin, it has an ongoing collaboration
Unified Parkinson's’ Disease Rating Scale, showing that it                   with Allergan Inc., of Irvine, Calif., for a Phase II-stage drug
did not worsen motor symptoms associated with the dis-                       for chronic pain and a Phase I program in glaucoma. And
ease. Pimavanserin also was found to be safe and well tol-                   it’s getting ready to start advancing additional programs
erated.                                                                      from its internal pipeline, starting with ACP-106, a selective
     Despite the disappointing data, Acadia remains confi-                   5-HT2A inverse agonist that is in investigational new drug
dent that the drug has “considerable potential” in PDP,                      application-track development. ■
Hacksell said. And the company is holding out hope that
the second Phase III trial of the selective 5-HT2A inverse
agonist, which is about a year behind the first, won’t be
thwarted by a similarly high placebo response.
                                                                               F    I N A N C I N G S                    RO       U N D U P
     That trial is designed with the same endpoints but is
testing 10-mg and 20-mg doses of pimavanserin.                                    • Alizé Pharma, of Lyon, France, has raised €3 million
     But a success in that case still won’t give Acadia a clear              (US$4.27 million) of funding. A new investor, SHAM, an
win.                                                                         insurance company, led the round. Existing investors,
     “We do believe we need two pivotal trials” before it can                Octalfa SAS and CEMA Inc. also participated. Including this
submit a regulatory filing, Hacksell said.                                   new round, Alizé Pharma Group has raised €4.8 million
     That means Acadia will have to consult with partner                     from those three investors since its creation in 2007. The
Biovail Corp.                                                                funds raised will allow Alizé Pharma to finalize the opti-
     Though Acadia funded both Phase III studies, terms of                   mization and formulation of a first drug candidate for AZP-
the May licensing deal call for Toronto-based Biovail to pick                01 and to file a clinical trial application to undertake the
up the tab for further development and commercialization                     clinical development of its Asparec product.
activities involving pimavanserin in PDP and any other neu-                       • Immunomedics Inc., of Morris Plains, N.J., filed
rological and psychiatric indications the companies decide                   papers with the SEC saying it planned to raise $151. 1 million
to pursue.                                                                   by selling stock and warrants. The company said it may
     As Piper Jaffray analyst Edward Tenthoff put it in a                    issue any combination of up to 20 million shares of com-
research note: “Without funding from Biovail, we believe                     mon stock and 3 million warrants. Last week the com-
pimavanserin development will be halted once studies in                      pany’s shares jumped 277 percent when epratuzumab had
PDP are complete.”                                                           a 24.9 percent treatment advantage over placebo in
     But even if the second PDP study fails, Hacksell said the               patients with systemic lupus erythematosus in a Phase IIb
drug has shown promise in other indications, including                       dosing study. (See BioWorld Today, Aug. 28, 2009.)

              To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                    Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, SEPTEMBER 2, 2009                                   BIOWORLD® TODAY                                                                PAGE 6 OF 7

Icagen                                                                       develop sodium ion channel modulators for pain, one of
Continued from page 1                                                        the pharma giant’s stated high-priority therapeutic areas.
renewal that would extend for another year,” he said.                        (See BioWorld Today, Aug. 15, 2007.)
     As of June 30, Icagen had about $24 million in cash and                      Outside of oncology, pain is considered by some as
cash equivalents, enough to operate “for at least the next 12                Pfizer’s biggest zone of interest. The firm “doesn’t jump to
months,” the company said in its quarterly financial filing,                 mind when you think of the major asthma companies,” Katz
but will need to raise money to operate beyond that time.                    conceded, but said he “would be surprised if they didn’t
     Shares of Icagen (NASDAQ:ICGN) closed Tuesday at                        have ongoing efforts in inflammatory indications, if not
$1.43, up 47 cents, or 49 percent, on word that the KCa3. 1                  asthma” itself.
channel blocker significantly reduced asthma over placebo                         Other large and “modest-sized” would-be partners
in patients given an inhaled allergen.                                       have expressed an interest in senicapoc, Katz told BioWorld
     Senicapoc fizzled in Phase III against sickle cell anemia               Today. “I’m not concerned that pharma is shying away from
two years ago, with Icagen stopping the trial after a moni-                  asthma,” he added, especially since the drug – unlike most
toring board found the study unlikely to yield positive data.                existing therapies – is orally delivered.
     “We had efficacy in terms of many of the secondary                           Partnering likely will wait until the next Phase II data
endpoints, but didn’t hit the primary endpoint, the control                  become available and maybe later, when the “multi-thou-
of crises,” Katz said, adding that senicapoc was “clearly                    sand-patient” Phase III asthma studies require deeper pock-
demonstrating biologic activity.”                                            ets, Katz said. ■
     The targeted channel is expressed on red blood cells
and white blood cells. Dehydration of red blood cells was
the problem Icagen sought to solve in sickle cell disease.                    O    T H E R             N    E W S          T    O         N   O T E
“In terms of effects on white blood cells [in immune disor-
ders], the channel becomes very important in controlling
the influx of calcium, even though it’s a potassium chan-                         • Affitech A/S, of Copenhagen, Denmark, appointed
nel,” Katz said.                                                             Robert Burns as CEO and Alexander Duncan as senior vice
     Results in the 34-patient, UK asthma trial were deter-                  president of research and development. Burns was previ-
mined by the drop in FEV1 , the volume of air that can be                    ously CEO of Celldex Therapeutics Inc., while Duncan hails
forcibly exhaled in one second. Improvement in the aver-                     from AstraZeneca plc. The appointments follow Affitech’s
age FEV1 decline was 29 percent (p = 0.06). In the maximum                   merger with Pharmexa A/S. (See BioWorld Today, March 5,
decline, the number was 18 percent (p = 0. 15), the area                     2009.)
under the curve amounted to 28 percent (p = 0.08) of FEV1.                        • Applied NeuroSolutions Inc., of Vernon Hills, Ill.,
     A secondary endpoint, the fraction of exhaled nitric                    appointed Craig S. Taylor as its president, CEO and a mem-
oxide (a measure of airway inflammation, typically high in                   ber of its board. Previously a partner at Adams Street Part-
asthmatic patients), dropped by 24 percent (p = 0. 10)                       ners LLC, Taylor served as associate director of business
among drug patients compared to those on placebo.                            development for G.D. Searle (now part of Pfizer) and was a
Another secondary endpoint – early asthmatic response –                      senior research biochemist at Abbott Laboratories.
didn’t change, a finding in line with preclinical results.                        • Basilea Pharmaceutica Ltd., of Basel, Switzerland,
     Senicapoc was well tolerated, with no serious adverse                   said that the FDA considers the response submitted by the
events. Icagen plans to offer full results at an upcoming                    sponsor Johnson & Johnson Pharmaceutical Research
scientific conference.                                                       & Development LLC, of Raritan, N.J., as a complete, class 2
     Meanwhile, the company has finished enrollment in a                     response. The submission addresses the FDA’s November
69-patient U.S. trial testing senicapoc in exercise-induced                  2008 letter concerning the ceftobiprole new drug applica-
asthma, with the same FEV1 endpoint. Data are expected in                    tion for complicated skin and skin structure infections.
the fourth quarter of this year.                                             Ceftobiprole is being developed through an exclusive world-
     In June, Icagen signed J.P. Morgan to help figure out                   wide collaboration between Basilea Pharmaceutica Inter-
next steps. Senicapoc’s 2007 failure in sickle cell was fol-                 national Ltd., also of Basel, and Cilag GmbH International, a
lowed by the loss of the related deals with McNeil Con-                      J&J company. (See BioWorld Today, Dec. 1, 2008.)
sumer & Specialty Pharmaceuticals, a subsidiary of New                            • Bristol-Myers Squibb Co., of New York, completed
Brunswick, N.J.-based Johnson & Johnson.                                     its tender offer for shares of Medarex Inc., of Princeton,
     Shortly afterward, Bristol-Myers Squibb Co., of New                     N.J. As of the expiration of the offering period, Medarex
York, backed away, deciding not to pursue development of                     shareholders tendered about 120.4 million shares, which,
the lead compound discovered in a long-standing deal tar-                    along with the 2.9 million shares owned by BMS since
geting atrial fibrillation.                                                  2005, represented about 90.7 percent of the shares out-
     Better news followed in the same year, when New York-                   standing. The two firms agreed to the $2.4 billion acquisi-
based Pfizer inked a potential $1 billion-plus deal to                       tion in July. (See BioWorld Today, July 24, 2009.)

              To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                    Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, SEPTEMBER 2, 2009                                   BIOWORLD® TODAY                                                            PAGE 7 OF 7

                                                                             said it now anticipates that its total operating expenses
O    T H E R          N    E W S          T    O      N    O T E             for 2009 will range between $78 million and $83 million,
                                                                             vs. its previous guidance of operating expenses ranging
                                                                             between $83 million and $88 million. It will continue to
     • Cellectis SA, of Romainville, France, and Mon-                        maintain sales coverage of the physicians with the highest
santo Co., of St. Louis, entered into a nonexclusive                         potential to prescribe Moxatag (extended-release amoxi-
research and commercial license agreement for broad use                      cillin) Tablets, 775 mg.
of Celectis’ meganuclease technology in plants. Cellectis                          • Neurobiological Technologies Inc., of Emeryville,
will receive an up-front payment of €3 million (US$ 4.2                      Calif., has decided to liquidate the company’s assets and to
million), Monsanto will make an equity investment of €1                      dissolve the company. The company intends to distribute
million to allow Cellectis to scale the technology for agri-                 the majority of its available cash to its stockholders. A
culture. Cellectis also will be eligible to receive fees for                 stockholders meeting will be held to vote on the plan. As of
the development of each meganuclease, success-based                          June 30, the company reported having cash, cash equiva-
milestones and may receive royalties on certain traits                       lents and short-term investments of $24 million,
commercialized by Monsanto. Further financial details                              • Nuvo Research Inc., of Missisauga, Ontario, has
were not disclosed.                                                          entered into a cooperative drug development project with
     • Champions Biotechnology Inc., of Baltimore,                           the Fraunhofer Institute for Cell Therapy and Immunology
entered a deal with an undisclosed large biotech company                     IZI in Leipzig, Germany, for the preclinical and clinical
to evaluate an oncology therapeutic using Champion’ Bio-                     development of WF10 as a potential treatment for allergic
merk Tumorgraft platform, which is designed to enable                        rhinitis. The Development Bank of Saxony in Germany will
identification of the most promising development path for                    provide financial support for the project, which will be con-
a compound and also identify potential gene pathways of                      ducted in Leipzig through Nuvo Research GmbH, a Nuvo
response and resistance, as well as prognostic molecular                     subsidiary.
biomarkers. Terms were not disclosed.                                              • Selexis SA, of Geneva, and NKT Therapeutics Inc.,
     • Clinical Data Inc., of Newton, Mass., sold the                        of Waltham, Mass., entered a research services deal under
equipment and property associated with its wholly                            which Selexis will screen antibody variants and generate
owned subsidiary – Germantown, Md.-based Avalon Phar-                        Chinese hamster ovary-based production cell lines using
maceuticals Inc. – to Blacksburg, Va.-based Intrexon                         its Integra-D2M
Corp. for $1.5 million cash. Clinical Data retains Avalon’s                        • Shire plc, of Basingstoke, UK, said its final two Phase
oncology drug candidates, intellectual property and bio-                     III trials for enzyme replacement therapy velaglucerase alfa
marker discovery platform, while Intrexon gets access to                     met their endpoints in Type I Gaucher’s disease and the
a bioassay platform to complement its transgene engi-                        company’s rolling new drug application at the FDA has
neering platform.                                                            been completed. (See BioWorld Today, Aug. 4, 2009.)
     • Medivir AB, of Stockholm, Sweden, selected MIV-71 1                         • SkyePharma plc, of London, said that additional
as a candidate drug for bone diseases. MIV-71 1 is a small-                  clinical work will be required to provide more data on dos-
molecule protease cathepsin K inhibitor distinguishable                      ing for its lead development product, Flutiform (fluticasone
from MIV-710, and both drugs are being prioritized over                      propionate/formoterol fumarate), for persistent asthma in
MIV-701 for osteoporosis, osteoarthritis, rheumatoid arthri-                 patients 12 years of age and older. The need for additional
tis and metastatic bone disease.                                             clinical work was confirmed in a meeting with the FDA, the
     • Metabasis Therapeutics Inc., of San Diego, said its                   company said. Due to the additional work, the board
president, CEO and chief scientific officer, Mark Erion,                     believes that it is unlikely that Flutiform will be approved in
resigned as an officer, effective Oct. 31. Erion, who also                   the U.S. before the second half of 201 1. In the meantime, the
resigned his position on the board, will consult with the                    FDA’s review of product is continuing.
company after that date on matters related to the licensing                        • Stemedica Cell Technologies Inc., of San Diego,
or sale of its pipeline and advanced discovery programs or                   has been granted a license by the California Food & Drug
other strategic alternatives. Erion is joining Whitehouse                    Branch to manufacture stem cells for human clinical trials.
Station, N.J.-based Merck & Co. Inc. as vice president and                   The license recognizes Stemedica as being compliant with
worldwide basis franchise head of diabetes and obesity.                      California law and the applicable provisions of the Code of
David Hale, Metabasis’ chairman, was appointed executive                     Federal Regulations.
chairman.                                                                          • Zealand Pharma AS, of Glostrup, Denmark, said it is
     • MiddleBrook Pharmaceuticals Inc., of Westlake,                        moving its new generation drug candidate for Type II dia-
Texas, has cut its sales managers and field sales represen-                  betes into preclinical development. The dual glucagon-GLP-
tatives by 25 percent and reduced corporate staff by                         1 agonist, ZP2929, has the potential to significantly
about 20 percent. As a result, the firm expects to achieve                   decrease body weight and reduce the risk of diabetes-
approximately $15 million in annual savings. The company                     related complications, the company said.

              To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                    Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
New from the Publishers of BioWorld® Today



     Market-Leading Biotechnology Drugs 2009:
           Blockbuster Dynamics in an Ailing Economy
           Giving you the insight needed to assess, and access, the dynamics that facilitate
                                    success in the biotech market.


 The new BioWorld's Market-Leading Biotechnology Drugs 2009 concisely delivers precise
 acumen on the history, trends, value and projection of the ever-increasingly imperative biotech
 drug therapeutics market that has emerged to the forefront of government initiatives, business
 agendas and public concern and is impacting many aspects of industry, economics and life.

 Viable business intelligence in this report includes:

 ✧ Which new technology is ordained to lead the fight against disease in the
     twenty-first century?
 ✧ Which drugmakers are projected to comprise the new list of large-cap                        BIOW
                                                                                                  ORL ®
                                                                                                     D
     biotechs in 2015?                                                              M
                                                                                BIOT ARKET-L
                                                                                    ECH         EAD
 ✧   Which biotech drug has the potential to be the first-ever drug to         BLO
                                                                                   CKB
                                                                                         NOL
                                                                                             OGY
                                                                                                   ING
                                                                                       UST        DRU
     generate $10 billion in annual revenue?
                                                                              IN A         ER D
                                                                                  NA                 GS:
                                                                                      ILIN     YNA
                                                                                          GE       MIC
 ✧   What is the prevailing trend that will define the biotech drug                           CON
                                                                                                  OM
                                                                                                     Y
                                                                                                       S

     market in the next decade?
 ✧   Which Big Biotech is undergoing FOB competition before its
     patents even expire, putting $4 billion in sales at risk?
 ✧   What are the 41 drugs that accounted for $35 billion in 2008
     revenuethat will lose patent exclusivity through 2012?
 ✧   Which drugmakers are expected to comprise the new list of large-cap biotechs in
     2015?
 ✧   And much more!

 Drugs are winning the containment battle, but disease is winning the war and the dynamics are
 constantly changing. Keep up-to-date with BioWorld's Market-Leading Biotechnology Drugs
 2009. This report is focused, nimble, efficient, meticulous, precise and value-packed.

Order BioWorld's Market-Leading Biotechnology Drugs 2009 risk-free for 30 days for only $199 (plus
$17.95 s&h). Call us at 1-800-688-2421 or 1-404-262-5476 or go to www.bioworld.com/biodrugs.

You may review this product risk-free for 30 days. If you do not wish to keep the product, please
return the product, together with the invoice marked "Cancel" to AHC at 4401 Freidrich Lane, Suite
205 Austin, TX 78744-1849. Shipping and handling charges for returned items are the responsibility of
the customer. If you have any questions or concerns you may contact us at 800-688-2421 or by e-
mailing customerservice@ahcmedia.com.


                                              ORDER TODAY!
              Call: 1-800-688-2421 or 1-404-262-5476 and mention priority code S09447.
              Online: Go to www.bioworld.com/biodrugs E-mail: orders@bioworld.com

Weitere ähnliche Inhalte

Ähnlich wie Sample

Bwt05212010
Bwt05212010Bwt05212010
Bwt05212010penneyh
 
Bwt09022009
Bwt09022009Bwt09022009
Bwt09022009penneyh
 
BioWorldToday03082016
BioWorldToday03082016BioWorldToday03082016
BioWorldToday03082016steve666
 
Developing Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic SpeedDeveloping Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic SpeedValentina Corona
 
The r dna protein market
The r dna protein marketThe r dna protein market
The r dna protein marketMai Ramos
 
Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccinatio...
Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccinatio...Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccinatio...
Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccinatio...RealLifeMurderMyster
 
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...MilliporeSigma
 
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...Merck Life Sciences
 
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018"."Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".Rosmirella Cano Rojas
 
Abreos biosciences I-Corps@ NIH 121014
Abreos biosciences I-Corps@ NIH 121014Abreos biosciences I-Corps@ NIH 121014
Abreos biosciences I-Corps@ NIH 121014Stanford University
 
Necessity of COVID-19 vaccination in previously infected individuals
Necessity of COVID-19 vaccination in previously infected individualsNecessity of COVID-19 vaccination in previously infected individuals
Necessity of COVID-19 vaccination in previously infected individualsMattisHallsteinVolla
 
Coronavirus Pandemic Part III (B): Therapeutic Options
Coronavirus Pandemic Part III (B): Therapeutic OptionsCoronavirus Pandemic Part III (B): Therapeutic Options
Coronavirus Pandemic Part III (B): Therapeutic OptionsKumaraguru Veerasamy
 
Developing Drug against COVID-19
Developing Drug against COVID-19Developing Drug against COVID-19
Developing Drug against COVID-19Suhaib Siddiqi
 
Can Canadian Vaccine Research Survive the Challenges of Globalization?
Can Canadian Vaccine Research Survive the Challenges of Globalization?Can Canadian Vaccine Research Survive the Challenges of Globalization?
Can Canadian Vaccine Research Survive the Challenges of Globalization?pcirnkt
 
Medicago Investor Presentation 2009
Medicago Investor Presentation 2009Medicago Investor Presentation 2009
Medicago Investor Presentation 2009Medicago
 

Ähnlich wie Sample (20)

Bwt05212010
Bwt05212010Bwt05212010
Bwt05212010
 
Bwt09022009
Bwt09022009Bwt09022009
Bwt09022009
 
BioWorldToday03082016
BioWorldToday03082016BioWorldToday03082016
BioWorldToday03082016
 
Nnvc 6262013
Nnvc 6262013Nnvc 6262013
Nnvc 6262013
 
Medical Device Daily - April 8, 2013
Medical Device Daily - April 8, 2013Medical Device Daily - April 8, 2013
Medical Device Daily - April 8, 2013
 
Developing Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic SpeedDeveloping Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic Speed
 
The r dna protein market
The r dna protein marketThe r dna protein market
The r dna protein market
 
Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccinatio...
Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccinatio...Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccinatio...
Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccinatio...
 
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
 
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
 
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018"."Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
 
Arntzen
ArntzenArntzen
Arntzen
 
Abreos biosciences I-Corp121014
Abreos biosciences I-Corp121014Abreos biosciences I-Corp121014
Abreos biosciences I-Corp121014
 
Abreos biosciences I-Corps@ NIH 121014
Abreos biosciences I-Corps@ NIH 121014Abreos biosciences I-Corps@ NIH 121014
Abreos biosciences I-Corps@ NIH 121014
 
2009 DEADLY VACCINE DEVELOPMENT
2009 DEADLY VACCINE DEVELOPMENT2009 DEADLY VACCINE DEVELOPMENT
2009 DEADLY VACCINE DEVELOPMENT
 
Necessity of COVID-19 vaccination in previously infected individuals
Necessity of COVID-19 vaccination in previously infected individualsNecessity of COVID-19 vaccination in previously infected individuals
Necessity of COVID-19 vaccination in previously infected individuals
 
Coronavirus Pandemic Part III (B): Therapeutic Options
Coronavirus Pandemic Part III (B): Therapeutic OptionsCoronavirus Pandemic Part III (B): Therapeutic Options
Coronavirus Pandemic Part III (B): Therapeutic Options
 
Developing Drug against COVID-19
Developing Drug against COVID-19Developing Drug against COVID-19
Developing Drug against COVID-19
 
Can Canadian Vaccine Research Survive the Challenges of Globalization?
Can Canadian Vaccine Research Survive the Challenges of Globalization?Can Canadian Vaccine Research Survive the Challenges of Globalization?
Can Canadian Vaccine Research Survive the Challenges of Globalization?
 
Medicago Investor Presentation 2009
Medicago Investor Presentation 2009Medicago Investor Presentation 2009
Medicago Investor Presentation 2009
 

Mehr von performanceweb (20)

Cheatsheet
CheatsheetCheatsheet
Cheatsheet
 
5 Deadly Workplace Legal Risks
5 Deadly Workplace Legal Risks5 Deadly Workplace Legal Risks
5 Deadly Workplace Legal Risks
 
T354
T354T354
T354
 
T354
T354T354
T354
 
T358
T358T358
T358
 
T354
T354T354
T354
 
T354 asmi
T354 asmiT354 asmi
T354 asmi
 
T358
T358T358
T358
 
P769
P769P769
P769
 
P769
P769P769
P769
 
E136
E136E136
E136
 
B331
B331B331
B331
 
P765
P765P765
P765
 
P765
P765P765
P765
 
P765
P765P765
P765
 
T354 pi
T354 piT354 pi
T354 pi
 
T354
T354T354
T354
 
B329
B329B329
B329
 
B316
B316B316
B316
 
T355
T355T355
T355
 

Kürzlich hochgeladen

PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfHajeJanKamps
 
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003believeminhh
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinAnton Skornyakov
 
Chicago Medical Malpractice Lawyer Chicago Medical Malpractice Lawyer.pdf
Chicago Medical Malpractice Lawyer Chicago Medical Malpractice Lawyer.pdfChicago Medical Malpractice Lawyer Chicago Medical Malpractice Lawyer.pdf
Chicago Medical Malpractice Lawyer Chicago Medical Malpractice Lawyer.pdfSourav Sikder
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfHajeJanKamps
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024Stephan Koning
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023Steve Rader
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursKaiNexus
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGlokeshwarmaha
 
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)tazeenaila12
 
Mihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZMihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZKanakChauhan5
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.ukaroemirsr
 
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...AustraliaChapterIIBA
 
Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..dlewis191
 
MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor PresentationMoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentationbaron83
 

Kürzlich hochgeladen (20)

PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
 
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup Berlin
 
Chicago Medical Malpractice Lawyer Chicago Medical Malpractice Lawyer.pdf
Chicago Medical Malpractice Lawyer Chicago Medical Malpractice Lawyer.pdfChicago Medical Malpractice Lawyer Chicago Medical Malpractice Lawyer.pdf
Chicago Medical Malpractice Lawyer Chicago Medical Malpractice Lawyer.pdf
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdf
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, Ours
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
 
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
 
Mihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZMihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZ
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.uk
 
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
 
Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..
 
MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor PresentationMoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentation
 
Investment Opportunity for Thailand's Automotive & EV Industries
Investment Opportunity for Thailand's Automotive & EV IndustriesInvestment Opportunity for Thailand's Automotive & EV Industries
Investment Opportunity for Thailand's Automotive & EV Industries
 

Sample

  • 1. BIOTECH’S MOST RESPECTED NEWS SOURCE FOR OVER 17 YEARS WEDNESDAY VOLUME 20, NO. 169 SEPTEMBER 2, 2009 PAGE 1 OF 7 Celgene Likes PTC’s GEMS, Too FDA Panel: More Clolar Data PTC Gets $12M Up Front in Needed for Approval in AML Roche Deal Worth up to $1.9B By Donna Young By Trista Morrison Washington Editor Staff Writer SILVER SPRING Md. – An FDA advisory panel Tuesday PTC Therapeutics Inc. is expected to announce two said more data were needed to validate the efficacy and drug discovery deals on Wednesday, a potential $1.9 billion safety of drugs from Genzyme Corp. and Vion Pharmaceu- whopper with Roche AG and an option exercise by Celgene ticals Inc. to treat elderly patients with acute myeloid Corp. for which terms were not disclosed. leukemia (AML), stating that the firms’ single-arm Phase II Both deals center on PTC’s Gene Expression Modula- studies were insufficient on which to base approval. tion by Small-molecules (GEMS) technology platform, Shares of Genzyme (NASDAQ:GENZ) closed at $55.39, which identifies small molecules that regulate post-tran- down 32 cents, while shares of Vion (OTC BB:VION) scriptional control mechanisms. plunged 23 percent, or 77 cents, to close at $2.60. In the Roche deal, PTC will get $12 million up front as In a 9-to-3 vote, the FDA Oncologic Drugs Advisory well as research funding to find small molecules that hit Committee (ODAC) said Genzyme should be required to four jointly selected central nervous system disease tar- conduct a randomized controlled trial before regulators gets. Each target could eventually bring up to $239 million consider approving Clolar (clofarabine) as a first-line treat- in research, development, regulatory and commercial ment for adults 60 years or older with AML with at least See PTC, Page 3 See FDA, Page 4 One Down, One Left: Acadia’s Pain Deal Still in Place Pimavanserin Fails in Phase III Icagen’s Phase II Asthma Win: By Jennifer Boggs Added Lure for Pfizer Buyout? Assistant Managing Editor By Randy Osborne Any expectations raised in May when Acadia Pharma- Staff Writer ceuticals Inc. impressed investors with a potentially lucra- Partner-forsaken Icagen Inc.’s upward stock ride on tive North American partnership for Phase III-stage pima- top-line Phase IIa news in allergic asthma with senicapoc vanserin were dashed when the drug failed to hit its pri- gives the firm a leg up during its ongoing exploration of mary endpoint in the first of two pivotal studies in Parkin- strategic alternatives, and just might lure pain collaborator son’s disease psychosis. Pfizer Inc. to the table for takeover talks. News sent the San Diego-based firm’s stock (NASDAQ: “I wouldn’t rule that out as a possibility,” said Richard ACAD), which had run up in the weeks ahead of the data, D. Katz, chief financial officer of Research Triangle Park, plunging 66 percent, or $3.84, to close Tuesday at $2. N.C.-based Icagen. Top-line data from the six-week, 298-patient trial Research funding for pain research from Pfizer (soon showed improvements in both treatment arms, according to merge with Wyeth, of Madison, N.J.) was slated to end the Scale for the Assessment of Positive Symptoms, but this month, but the deal was extended for six weeks, Katz Acadia said a higher-than-expected response in the said. placebo arm prevented the study from meeting statistical “We’re in the process of discussing with them a See Acadia, Page 5 See Icagen, Page 6 INSIDE: NOVAVAX TURNS TO FUNDING AS VLP VACCINE PASSES MIDSTAGE..............2 CLINIC ROUNDUP ..........................................................................................3 To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 2. WEDNESDAY, SEPTEMBER 2, 2009 BIOWORLD® TODAY PAGE 2 OF 7 Second Phase II Trial Positive strains targeted for the 2008-2009 flu season, Singhvi Novavax Will Need More Cash explained. Novavax has now shown that the VLP vaccine candidate could work in different formulations, he said. to Push VLP Vaccine Farther Novavax hopes that its vaccine candidate, which is By Catherine Hollingsworth made in cell cultures, will stand apart from those that are Staff Writer made in egg cultures, which can have a lengthy cultivation Novavax reported positive results from a second Phase period. Novavax’s vaccine candidate has the potential to be II trial of its trivalent seasonal influenza virus-like particle made faster for annual flu season. (VLP) vaccine candidate. Another distinction is that Novavax’s VLP vaccine can- The Rockville, Md.-based company has a Spain-based didate includes three viral proteins important for inducing partner, ROVI Pharmaceutical Laboratories SA, that is help- a broad immune response: two surface proteins, hemag- ing to fund the VLP vaccine studies through Phase III and glutinin (HA) and neuraminidase (NA), and a core matrix ultimately toward an anticipated regulatory approval in protein, M1. Most seasonal vaccines consist almost entirely Europe. of HA with little or no NA and M1 , according to the com- But the company will need additional funding to satisfy pany’s website. FDA requirements, Rahul Singhvi, president and CEO of The HA protein induces an antibody that neutralizes or Novavax, told BioWorld Today. blocks the growth of the virus; NA induces antibodies that In the U.S., Novavax has said that it is seeking support prevent cell-to-cell transmission of virus down the respira- from the Health and Human Services Department’s Bio- tory tract, potentially reducing the severity of influenza medical Advanced Research and Development Authority. disease; and cell-mediated immune responses to M1 may The company also is considering a potential partner as it lead to destruction of cells already infected. seeks U.S. approval of the VLP product, Singhvi indicated. VLPs are recombinant structures that mimic the size In its most recent earnings report, Novavax reported and shape of a virus. They are incapable of replication but that it had close to $38 million in cash and no long-term can induce potent immune response, the company said. debt on its balance sheet. Rodman & Renshaw analyst Elemer Piros wrote in a The latest Phase II study of 221 patients showed that research note that “Novavax’s VLP vaccine technology is the VLP-based vaccine was well tolerated and induced truly revolutionary compared to the traditional egg-based robust immune responses against the three influenza vaccines.” strains (H3N2, H1N1 and B). The three strains were matched He added that the company’s developing seasonal vac- to the strains recommended for influenza vaccines during cine business “may be overlooked,” noting that it is apply- the past flu season, 2008-2009. ing its technology toward developing vaccines for respira- The positive outcome of the second Phase II study sup- tory syncytial virus, shingles, HIV, and severe acute respira- ported moving ahead with larger head-to-head trials of VLP tory syndrome as well as pandemic H1N1 vaccine. and egg-based vaccines, the first of which is scheduled to Its VLP-based vaccine against the H1N1 flu vaccine is start this fall in elderly adults, Novavax said. Phase III stud- advancing into preclinical development and could enter the ies are expected next year. clinic later this year. The company’s drug candidate for RSV The previous Phase II study also was positive. While the also is expected to be in the clinic next year, Singhvi said. first Phase II study involved a 2005-2006 formulation, the Shares in the Rockville, Md.-based company (NASDAQ: second study showed that the product worked against NVAX) rose 61 cents, to close at $6.65 Tuesday. ■ SUBSCRIBER INFORMATION BioWorld® Today (ISSN# 1541-0595) is published every business day by AHC Media LLC, 3525 Piedmont Road, Building Six, Suite 400, Atlanta, GA 30305 U.S.A. Opinions expressed are not necessarily those Please call (800) 688-2421 to subscribe of this publication. Mention of products or services does not constitute endorsement. BioWorld® and or if you have fax transmission problems. BioWorld® Today are trademarks of AHC Media LLC, a Thompson Publishing Group company. Copyright Outside U.S. and Canada, call (404) © 2009 AHC Media LLC. All Rights Reserved. No part of this publication may be reproduced without the 262-5476. Our customer service hours written consent of AHC Media LLC. (GST Registration Number R128870672). are 8:30 a.m. to 6:00 p.m. EST. Glen Harris, (404) 262-5408 ATLANTA NEWSROOM: Managing Editor: Glen Harris. Assistant Managing Editor: Jennifer Boggs. Jennifer Boggs, (404) 262-5427 Senior Staff Writer: Karen Pihl-Carey. Senior Production Editor: Ann Duncan. Anette Breindl, (518) 595-4041 Staff Writer: Randy Osborne. Trista Morrison, (858) 901-4785 WASHINGTON BUREAU: Washington Editor: Donna Young. Staff Writer: Catherine Hollingsworth. Donna Young, (202) 739-9556 WEST COAST BUREAU: Staff Writer: Trista Morrison. Catherine Hollingsworth, (301) 576-0667 EAST COAST BUREAU: Science Editor: Anette Breindl. Senior Vice President/Group Publisher: BUSINESS OFFICE: Senior Vice President/Group Publisher: Donald R. Johnston. Donald R. Johnston, (404) 262-5439 Senior Marketing Product Manager: Chris Walker. Internet: http://www.bioworld.com Marketing Coordinator: Sonia Blanco. Account Representatives: Bob Sobel, Randee Papush. DISPLAY ADVERTISING: For ad rates and information, please call Stephen Vance at (404) 262-5511 or email him at stephen.vance@ahcmedia.com. REPRINTS: For photocopy rights or reprints, call our reprints department at (404) 262-5479. PRESS MATERIALS: Send all press releases and related information to newsdesk@bioworld.com.
  • 3. WEDNESDAY, SEPTEMBER 2, 2009 BIOWORLD® TODAY PAGE 3 OF 7 PTC trophy and a pivotal Phase III trial for cystic fibrosis. A Continued from page 1 proof-of-concept trial in hemophilia also is under way, and milestone payments, plus double-digit royalties, and Roche Peltz said PTC is “just nailing down” a fourth program, has an option to add four more targets under the same which likely will focus on a metabolic disorder. PTC inked a terms. $437 million partnership with Genzyme Corp. on the drug All-told that’s $1.9 billion in potential milestones. PTC’s last year but retained U.S. and Canadian rights. (See senior vice president of corporate development, Cláudia BioWorld Today, July 18, 2008.) Hirawat, noted that the payments are spread across the Moving forward, “we think this is going to be a pretty development and commercialization continuum with no exciting next couple of years,” Peltz said. particular emphasis on the front or back end. In a time when many biotechs are struggling and Concurrent with the new Roche deal, PTC announced experts claim you can’t build a fully integrated pharmaceu- that Celgene exercised its option to partner on a GEMS tical company, PTC is well funded and moving the first of its oncology target. Two years ago, Celgene made a $20 mil- internally discovered candidates toward the commercial lion equity investment in PTC in exchange for options on realm. ■ two targets, and the exercise of one of them will trigger an undisclosed stream of discovery, development, regulatory and commercial milestone payments as well as royalties. (See BioWorld Today, Sept. 14, 2007.) C L I N I C RO U N D U P Roche and Celgene are only the latest to notice the sparkle of PTC’s GEMS. The company previously inked a • Ablynx NV, of Ghent Belgium, has begun a Phase II $212 million hepatitis C deal with Schering-Plough Corp., a study for its antithrombotic Nanobody ALX-0081 , a first-in- $345 million cardiovascular deal with CV Therapeutics Inc. class nanobody targeting von Willebrand Factor. The open- (now part of Gilead Sciences Inc.) and a $1.2 billion deal label, randomized study is designed to evaluate the safety with Pfizer Inc. (See BioWorld Today, March 21 , 2006, June and efficacy of multiple doses of ALX-0081 vs. the GPIIb/IIIa 13, 2006, and Jan. 9, 2007.) inhibitor ReoPro in patients undergoing percutaneous Stuart Peltz, president and CEO of PTC, explained that coronary intervention. Patients with unstable angina or the attraction of GEMS lies in its ability to provide control patients with stable angina with at least two factors indi- over difficult, intractable or uncharacterized protein tar- cating high risk will be included in the study. gets. • Antisoma plc, of London, said the ATTRACT-1 Phase While the middle of an RNA molecule serves as a blue- III trial of its tumor vasculature disrupting agent ASA404 in print for making proteins, the untranslated ends of the non-small-cell lung cancer (NSCLC) has reached its enroll- molecule determine how much protein gets made. By ment target of 1 ,200 patients. The trial is the single pivotal focusing on the untranslated ends, PTC’s GEMS platform registration study for the drug as a first-line treatment for churns out drugs that can increase or decrease the amount squamous and nonsquamous NSCLC, and is being con- of protein produced. In addition to providing a new ducted by Novartis AG, of Basel, Switzerland, Antisoma’s approach to tough targets, GEMS can be used to replace development and commercialization partner for ASA404. temperamental biologics with convenient small molecules, The company expects results will be available in time to Peltz said. support potential marketing applications in 201 1. PTC has its own GEMS molecule, PTC299, moving • Kowa Co. Ltd., of Tokyo, presented data showing through Phase II trials for breast cancer, solid tumors, that pitavastatin is noninferior to atorvastatin and simvas- Kaposi’s sarcoma associated with human immunodefi- tatin at usual therapeutic doses in patients with primary ciency virus infection and brain tumors associated with hypercholesterolemia or combined dyslipidemia, as meas- neurofibromatosis type 2. ured by reduction of low density lipoprotein cholesterol PTC299 targets vascular endothelial growth factor (LDL-C) from baseline. LDL-C target attainment data were (VEGF), placing it into a crowded field that includes Avastin similar when comparing pitavastatin to atorvastatin and (bevacizumab, Genentech/Roche) and loads of experimen- simvastatin, although pitavastatin demonstrated signifi- tal drugs, but Hirawat said PTC’s drug works “upstream of cantly higher LDL-C target attainment compared to sim- what everyone else is doing” and thus far hasn’t elicited vastatin in the lower dose study-arm (pitavastatin 2 mg vs. typical VEGF inhibitor side effects. simvastatin 20 mg) (p = 0.047). Continued gradual Yet the crown jewel of PTC’s pipeline has nothing to do increases in high density lipoprotein cholesterol were with GEMS. Ataluren (formerly PTC124) is based on PTC’s observed over the long-term, supported by data from a 52 nonsense suppression technology, which allows cellular week extension study. Pitavastatin also demonstrated a machinery to read through nonsense mutations in genetic favorable safety and tolerability profile to 52 weeks. Data disorders, resulting in production of a functional protein. were presented at the European Society of Cardiology Ataluren is in a pivotal Phase IIb trial for muscular dys- meeting in Barcelona, Spain. To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 4. WEDNESDAY, SEPTEMBER 2, 2009 BIOWORLD® TODAY PAGE 4 OF 7 FDA ated approval was for a “fairly timely” completion of follow- Continued from page 1 up studies. one unfavorable baseline prognostic factor. Michael Vasconcelles, group vice president and global A larger ODAC panel in the afternoon voted 13 to 0 that therapeutic area head of transplant and oncology at Gen- Vion also be required to conduct a randomized trial of zyme, said the early combination safety studies, which will Onrigin (laromustine) to establish the safety and efficacy of serve as the basis of the randomized Phase III pediatric the drug as a single agent for remission induction in trial, were initiated “immediately after” the accelerated patients 60 years or older with de novo, poor-risk AML. approval was granted and have been ongoing for the past AML, the most common type of acute leukemia, affects four years. elderly adults very differently than younger patients with Mark Enyedy, head of oncology and multiple sclerosis the disease. Elderly patients have higher risk factors and at Genzyme, told reporters after the meeting that the com- have lower response rates, with shorter overall survival. pany has had a “strong track record” of fulfilling postap- Genzyme and Vion argued that their drugs would fill an proval commitments. “Genzyme is one of the companies in unmet need for elderly patients, a population for which the industry that has completed those postapproval com- two-thirds typically go untreated because of the poorer mitments,” he contended. outcomes. Genzyme submitted its supplemental application for In Genzyme’s CLO243 study, 51 of 1 12 patients, or 45.5 AML in elderly patients to the FDA in November 2008 based percent, achieved overall remission, defined as either com- on its single-arm Phase II CLO243 trial of Clolar in older adult plete remission or complete remission with incomplete patients with previously untreated AML who were deemed platelet recovery. Of the 51 responders, 38, or 74.5 percent, unfit for conventional treatment with seven days of continu- achieved OR after one cycle of Clolar and 13, or 25.5 per- ous infusion cytarabine plus three days of an anthracycline cent, achieved OR after two cycles. or anthracenedione, known as 7+3 induction chemotherapy. In Vion’s single-arm CLI-043 study, 27 of 85 patients, or The company also submitted data from a supportive 31.8 percent, achieved OR. In the company’s CLI-033 sup- multicenter, single-arm study, known as BIOV-121 , in a sim- portive single-arm study, 38.2 percent of patients achieved ilar population. OR. Across all 140 elderly de novo poor-risk AML patients in Mark Hayes, group vice president of regulatory affairs at both studies, 34.3 percent achieved OR. Genzyme, said the company had proposed a randomized Although the ODAC panelists agreed that the remission controlled trial and submitted a special protocol assessment rates were impressive, they were unconvinced that the Gen- to the FDA for study CLO342 in March 2006 of Clolar in com- zyme’s and Vion’s single-arm studies were sufficient to show bination with low-dose cytarabine vs. low-dose cytarabine that the drugs’ benefits outweighed the risks or that it was alone in previously untreated older adults with AML. clear that the medications were any better than chemotherapy. But, he said, a panel of outside AML experts who Richard Pazdur, director of the FDA’s Office of Oncol- reviewed the study protocol for Genzyme could not agree ogy Drug Products, noted that the agency had urged both on an appropriate comparator arm for the proposed study companies to conduct randomized controlled trials before population and recommended a single-arm, single-agent submitting their applications – advice that went unheeded clinical study instead. by Genzyme and Vion. But Pazdur noted that the FDA has heard similar argu- Clolar already is marketed in the U.S. The FDA in 2004 ments before from drugmakers. granted accelerated approval for the drug as treatment for “This is a common, common comment,” he said. Pazdur pediatric patients with relapsed or refractory acute lym- argued that companies have several options for compara- phoblastic leukemia after at least two prior regimens. The tor arms, including using investigational drugs. company has a commitment to complete a Phase III study Genzyme currently has an ongoing Phase III random- of the drug in pediatric patients to gain full approval in that ized, double-blind, placebo-controlled study comparing population. Clolar plus intermediate-dose cytarabine vs. intermediate- Pazdur, however, appeared to lob a warning shot dose cytarabine alone in adult patients 55 years or older across the bow by calling out the fact that the company has with relapsed or refractory AML after receiving up to two yet to start that trial six years after the approval. prior induction regimens. Genzyme officials said the company is nearing com- But panelists noted that the population in that trial is pletion of its Phase I/II development program of Clolar in very different in age and disease type as the population Gen- combination with chemotherapy and plans to start the zyme is seeking approval for in its supplemental application. Phase III randomized controlled trial in newly diagnosed Vion’s application primarily relies on the findings of a children in 2010. single-arm study and a post-hoc subset of patients from a But panelist Thomas Fleming, a professor of biostatis- second single-arm study. The company also submitted data tics at the University of Washington in Seattle, scolded Gen- from a randomized controlled trial, which was placed on zyme, asserting that the “congressional intent” of acceler- clinical hold due to excess death in the Onrigin arm. ■ To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 5. WEDNESDAY, SEPTEMBER 2, 2009 BIOWORLD® TODAY PAGE 5 OF 7 Acadia Alzheimer’s disease psychosis, schizophrenia and insom- Continued from page 1 nia. The companies already selected ADP as the second significance. Mean reductions in SAPS scores were 5.8 indication to explore and “we’ll decide on a path forward points in the 10-mg pimavanserin arm, 6.7 points in the 40- after we analyze the data” from the first PDP study, he mg arm and 5.9 points in the placebo group. added. The company plans further analysis, but executives Nevertheless, the first Phase III failure marked a set- said they were at a loss to explain the high placebo back for the firm, which had been riding high since pleas- response. While the drug missed the SAPS endpoint in an antly surprising analysts and investors with its potential earlier Phase II study, “we got a very nice separation $395 million Biovail deal. That partnership, coming before between the treatment and placebo [groups],” Acadia CEO the release of Phase III data, sent the company’s stock soar- Uli Hacksell told BioWorld Today. ing 134 percent and seemed to quell some of the doubt sur- During the firm’s conference call, executives said a pre- rounding pimavanserin’s efficacy following mixed Phase II vious four-week study had shown a change from baseline data. (See BioWorld Today, May 5, 2009.) of only 1. 1 points in the placebo study, and investigators It also offered some reassurance for investors skeptical were expecting a similar trend in the Phase III trial, which about the drug’s potential in the PDP market. There are no was 90 percent powered for a 5-point difference between FDA-approved drugs specifically for PDP, but there are treatment and placebo. generic atypical antipsychotics that are used off-label, with SAPS is the recommended endpoint to describe psy- limited efficacy. The most efficacious of those is clozapine, chosis in Parkinson's disease, a condition involving halluci- but it carries several well-known side effects. nations and delusions that affects about 40 percent of the Acadia, which earned $30 million up front from Biovail estimated 1.5 million U.S. patients with Parkinson’s, Hack- in its May licensing deal, had about $66.2 million in the sell said. bank as of June 30. The firm said it expects to end this year All patients enrolled in the study remained on their sta- with more than $40 million, enough to carry it into the first ble doses of dopamine drugs, and the study met its sec- half of 201 1. ondary endpoint of motoric tolerability, as measured by the Beyond pimavanserin, it has an ongoing collaboration Unified Parkinson's’ Disease Rating Scale, showing that it with Allergan Inc., of Irvine, Calif., for a Phase II-stage drug did not worsen motor symptoms associated with the dis- for chronic pain and a Phase I program in glaucoma. And ease. Pimavanserin also was found to be safe and well tol- it’s getting ready to start advancing additional programs erated. from its internal pipeline, starting with ACP-106, a selective Despite the disappointing data, Acadia remains confi- 5-HT2A inverse agonist that is in investigational new drug dent that the drug has “considerable potential” in PDP, application-track development. ■ Hacksell said. And the company is holding out hope that the second Phase III trial of the selective 5-HT2A inverse agonist, which is about a year behind the first, won’t be thwarted by a similarly high placebo response. F I N A N C I N G S RO U N D U P That trial is designed with the same endpoints but is testing 10-mg and 20-mg doses of pimavanserin. • Alizé Pharma, of Lyon, France, has raised €3 million But a success in that case still won’t give Acadia a clear (US$4.27 million) of funding. A new investor, SHAM, an win. insurance company, led the round. Existing investors, “We do believe we need two pivotal trials” before it can Octalfa SAS and CEMA Inc. also participated. Including this submit a regulatory filing, Hacksell said. new round, Alizé Pharma Group has raised €4.8 million That means Acadia will have to consult with partner from those three investors since its creation in 2007. The Biovail Corp. funds raised will allow Alizé Pharma to finalize the opti- Though Acadia funded both Phase III studies, terms of mization and formulation of a first drug candidate for AZP- the May licensing deal call for Toronto-based Biovail to pick 01 and to file a clinical trial application to undertake the up the tab for further development and commercialization clinical development of its Asparec product. activities involving pimavanserin in PDP and any other neu- • Immunomedics Inc., of Morris Plains, N.J., filed rological and psychiatric indications the companies decide papers with the SEC saying it planned to raise $151. 1 million to pursue. by selling stock and warrants. The company said it may As Piper Jaffray analyst Edward Tenthoff put it in a issue any combination of up to 20 million shares of com- research note: “Without funding from Biovail, we believe mon stock and 3 million warrants. Last week the com- pimavanserin development will be halted once studies in pany’s shares jumped 277 percent when epratuzumab had PDP are complete.” a 24.9 percent treatment advantage over placebo in But even if the second PDP study fails, Hacksell said the patients with systemic lupus erythematosus in a Phase IIb drug has shown promise in other indications, including dosing study. (See BioWorld Today, Aug. 28, 2009.) To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 6. WEDNESDAY, SEPTEMBER 2, 2009 BIOWORLD® TODAY PAGE 6 OF 7 Icagen develop sodium ion channel modulators for pain, one of Continued from page 1 the pharma giant’s stated high-priority therapeutic areas. renewal that would extend for another year,” he said. (See BioWorld Today, Aug. 15, 2007.) As of June 30, Icagen had about $24 million in cash and Outside of oncology, pain is considered by some as cash equivalents, enough to operate “for at least the next 12 Pfizer’s biggest zone of interest. The firm “doesn’t jump to months,” the company said in its quarterly financial filing, mind when you think of the major asthma companies,” Katz but will need to raise money to operate beyond that time. conceded, but said he “would be surprised if they didn’t Shares of Icagen (NASDAQ:ICGN) closed Tuesday at have ongoing efforts in inflammatory indications, if not $1.43, up 47 cents, or 49 percent, on word that the KCa3. 1 asthma” itself. channel blocker significantly reduced asthma over placebo Other large and “modest-sized” would-be partners in patients given an inhaled allergen. have expressed an interest in senicapoc, Katz told BioWorld Senicapoc fizzled in Phase III against sickle cell anemia Today. “I’m not concerned that pharma is shying away from two years ago, with Icagen stopping the trial after a moni- asthma,” he added, especially since the drug – unlike most toring board found the study unlikely to yield positive data. existing therapies – is orally delivered. “We had efficacy in terms of many of the secondary Partnering likely will wait until the next Phase II data endpoints, but didn’t hit the primary endpoint, the control become available and maybe later, when the “multi-thou- of crises,” Katz said, adding that senicapoc was “clearly sand-patient” Phase III asthma studies require deeper pock- demonstrating biologic activity.” ets, Katz said. ■ The targeted channel is expressed on red blood cells and white blood cells. Dehydration of red blood cells was the problem Icagen sought to solve in sickle cell disease. O T H E R N E W S T O N O T E “In terms of effects on white blood cells [in immune disor- ders], the channel becomes very important in controlling the influx of calcium, even though it’s a potassium chan- • Affitech A/S, of Copenhagen, Denmark, appointed nel,” Katz said. Robert Burns as CEO and Alexander Duncan as senior vice Results in the 34-patient, UK asthma trial were deter- president of research and development. Burns was previ- mined by the drop in FEV1 , the volume of air that can be ously CEO of Celldex Therapeutics Inc., while Duncan hails forcibly exhaled in one second. Improvement in the aver- from AstraZeneca plc. The appointments follow Affitech’s age FEV1 decline was 29 percent (p = 0.06). In the maximum merger with Pharmexa A/S. (See BioWorld Today, March 5, decline, the number was 18 percent (p = 0. 15), the area 2009.) under the curve amounted to 28 percent (p = 0.08) of FEV1. • Applied NeuroSolutions Inc., of Vernon Hills, Ill., A secondary endpoint, the fraction of exhaled nitric appointed Craig S. Taylor as its president, CEO and a mem- oxide (a measure of airway inflammation, typically high in ber of its board. Previously a partner at Adams Street Part- asthmatic patients), dropped by 24 percent (p = 0. 10) ners LLC, Taylor served as associate director of business among drug patients compared to those on placebo. development for G.D. Searle (now part of Pfizer) and was a Another secondary endpoint – early asthmatic response – senior research biochemist at Abbott Laboratories. didn’t change, a finding in line with preclinical results. • Basilea Pharmaceutica Ltd., of Basel, Switzerland, Senicapoc was well tolerated, with no serious adverse said that the FDA considers the response submitted by the events. Icagen plans to offer full results at an upcoming sponsor Johnson & Johnson Pharmaceutical Research scientific conference. & Development LLC, of Raritan, N.J., as a complete, class 2 Meanwhile, the company has finished enrollment in a response. The submission addresses the FDA’s November 69-patient U.S. trial testing senicapoc in exercise-induced 2008 letter concerning the ceftobiprole new drug applica- asthma, with the same FEV1 endpoint. Data are expected in tion for complicated skin and skin structure infections. the fourth quarter of this year. Ceftobiprole is being developed through an exclusive world- In June, Icagen signed J.P. Morgan to help figure out wide collaboration between Basilea Pharmaceutica Inter- next steps. Senicapoc’s 2007 failure in sickle cell was fol- national Ltd., also of Basel, and Cilag GmbH International, a lowed by the loss of the related deals with McNeil Con- J&J company. (See BioWorld Today, Dec. 1, 2008.) sumer & Specialty Pharmaceuticals, a subsidiary of New • Bristol-Myers Squibb Co., of New York, completed Brunswick, N.J.-based Johnson & Johnson. its tender offer for shares of Medarex Inc., of Princeton, Shortly afterward, Bristol-Myers Squibb Co., of New N.J. As of the expiration of the offering period, Medarex York, backed away, deciding not to pursue development of shareholders tendered about 120.4 million shares, which, the lead compound discovered in a long-standing deal tar- along with the 2.9 million shares owned by BMS since geting atrial fibrillation. 2005, represented about 90.7 percent of the shares out- Better news followed in the same year, when New York- standing. The two firms agreed to the $2.4 billion acquisi- based Pfizer inked a potential $1 billion-plus deal to tion in July. (See BioWorld Today, July 24, 2009.) To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 7. WEDNESDAY, SEPTEMBER 2, 2009 BIOWORLD® TODAY PAGE 7 OF 7 said it now anticipates that its total operating expenses O T H E R N E W S T O N O T E for 2009 will range between $78 million and $83 million, vs. its previous guidance of operating expenses ranging between $83 million and $88 million. It will continue to • Cellectis SA, of Romainville, France, and Mon- maintain sales coverage of the physicians with the highest santo Co., of St. Louis, entered into a nonexclusive potential to prescribe Moxatag (extended-release amoxi- research and commercial license agreement for broad use cillin) Tablets, 775 mg. of Celectis’ meganuclease technology in plants. Cellectis • Neurobiological Technologies Inc., of Emeryville, will receive an up-front payment of €3 million (US$ 4.2 Calif., has decided to liquidate the company’s assets and to million), Monsanto will make an equity investment of €1 dissolve the company. The company intends to distribute million to allow Cellectis to scale the technology for agri- the majority of its available cash to its stockholders. A culture. Cellectis also will be eligible to receive fees for stockholders meeting will be held to vote on the plan. As of the development of each meganuclease, success-based June 30, the company reported having cash, cash equiva- milestones and may receive royalties on certain traits lents and short-term investments of $24 million, commercialized by Monsanto. Further financial details • Nuvo Research Inc., of Missisauga, Ontario, has were not disclosed. entered into a cooperative drug development project with • Champions Biotechnology Inc., of Baltimore, the Fraunhofer Institute for Cell Therapy and Immunology entered a deal with an undisclosed large biotech company IZI in Leipzig, Germany, for the preclinical and clinical to evaluate an oncology therapeutic using Champion’ Bio- development of WF10 as a potential treatment for allergic merk Tumorgraft platform, which is designed to enable rhinitis. The Development Bank of Saxony in Germany will identification of the most promising development path for provide financial support for the project, which will be con- a compound and also identify potential gene pathways of ducted in Leipzig through Nuvo Research GmbH, a Nuvo response and resistance, as well as prognostic molecular subsidiary. biomarkers. Terms were not disclosed. • Selexis SA, of Geneva, and NKT Therapeutics Inc., • Clinical Data Inc., of Newton, Mass., sold the of Waltham, Mass., entered a research services deal under equipment and property associated with its wholly which Selexis will screen antibody variants and generate owned subsidiary – Germantown, Md.-based Avalon Phar- Chinese hamster ovary-based production cell lines using maceuticals Inc. – to Blacksburg, Va.-based Intrexon its Integra-D2M Corp. for $1.5 million cash. Clinical Data retains Avalon’s • Shire plc, of Basingstoke, UK, said its final two Phase oncology drug candidates, intellectual property and bio- III trials for enzyme replacement therapy velaglucerase alfa marker discovery platform, while Intrexon gets access to met their endpoints in Type I Gaucher’s disease and the a bioassay platform to complement its transgene engi- company’s rolling new drug application at the FDA has neering platform. been completed. (See BioWorld Today, Aug. 4, 2009.) • Medivir AB, of Stockholm, Sweden, selected MIV-71 1 • SkyePharma plc, of London, said that additional as a candidate drug for bone diseases. MIV-71 1 is a small- clinical work will be required to provide more data on dos- molecule protease cathepsin K inhibitor distinguishable ing for its lead development product, Flutiform (fluticasone from MIV-710, and both drugs are being prioritized over propionate/formoterol fumarate), for persistent asthma in MIV-701 for osteoporosis, osteoarthritis, rheumatoid arthri- patients 12 years of age and older. The need for additional tis and metastatic bone disease. clinical work was confirmed in a meeting with the FDA, the • Metabasis Therapeutics Inc., of San Diego, said its company said. Due to the additional work, the board president, CEO and chief scientific officer, Mark Erion, believes that it is unlikely that Flutiform will be approved in resigned as an officer, effective Oct. 31. Erion, who also the U.S. before the second half of 201 1. In the meantime, the resigned his position on the board, will consult with the FDA’s review of product is continuing. company after that date on matters related to the licensing • Stemedica Cell Technologies Inc., of San Diego, or sale of its pipeline and advanced discovery programs or has been granted a license by the California Food & Drug other strategic alternatives. Erion is joining Whitehouse Branch to manufacture stem cells for human clinical trials. Station, N.J.-based Merck & Co. Inc. as vice president and The license recognizes Stemedica as being compliant with worldwide basis franchise head of diabetes and obesity. California law and the applicable provisions of the Code of David Hale, Metabasis’ chairman, was appointed executive Federal Regulations. chairman. • Zealand Pharma AS, of Glostrup, Denmark, said it is • MiddleBrook Pharmaceuticals Inc., of Westlake, moving its new generation drug candidate for Type II dia- Texas, has cut its sales managers and field sales represen- betes into preclinical development. The dual glucagon-GLP- tatives by 25 percent and reduced corporate staff by 1 agonist, ZP2929, has the potential to significantly about 20 percent. As a result, the firm expects to achieve decrease body weight and reduce the risk of diabetes- approximately $15 million in annual savings. The company related complications, the company said. To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2009 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 8. New from the Publishers of BioWorld® Today Market-Leading Biotechnology Drugs 2009: Blockbuster Dynamics in an Ailing Economy Giving you the insight needed to assess, and access, the dynamics that facilitate success in the biotech market. The new BioWorld's Market-Leading Biotechnology Drugs 2009 concisely delivers precise acumen on the history, trends, value and projection of the ever-increasingly imperative biotech drug therapeutics market that has emerged to the forefront of government initiatives, business agendas and public concern and is impacting many aspects of industry, economics and life. Viable business intelligence in this report includes: ✧ Which new technology is ordained to lead the fight against disease in the twenty-first century? ✧ Which drugmakers are projected to comprise the new list of large-cap BIOW ORL ® D biotechs in 2015? M BIOT ARKET-L ECH EAD ✧ Which biotech drug has the potential to be the first-ever drug to BLO CKB NOL OGY ING UST DRU generate $10 billion in annual revenue? IN A ER D NA GS: ILIN YNA GE MIC ✧ What is the prevailing trend that will define the biotech drug CON OM Y S market in the next decade? ✧ Which Big Biotech is undergoing FOB competition before its patents even expire, putting $4 billion in sales at risk? ✧ What are the 41 drugs that accounted for $35 billion in 2008 revenuethat will lose patent exclusivity through 2012? ✧ Which drugmakers are expected to comprise the new list of large-cap biotechs in 2015? ✧ And much more! Drugs are winning the containment battle, but disease is winning the war and the dynamics are constantly changing. Keep up-to-date with BioWorld's Market-Leading Biotechnology Drugs 2009. This report is focused, nimble, efficient, meticulous, precise and value-packed. Order BioWorld's Market-Leading Biotechnology Drugs 2009 risk-free for 30 days for only $199 (plus $17.95 s&h). Call us at 1-800-688-2421 or 1-404-262-5476 or go to www.bioworld.com/biodrugs. You may review this product risk-free for 30 days. If you do not wish to keep the product, please return the product, together with the invoice marked "Cancel" to AHC at 4401 Freidrich Lane, Suite 205 Austin, TX 78744-1849. Shipping and handling charges for returned items are the responsibility of the customer. If you have any questions or concerns you may contact us at 800-688-2421 or by e- mailing customerservice@ahcmedia.com. ORDER TODAY! Call: 1-800-688-2421 or 1-404-262-5476 and mention priority code S09447. Online: Go to www.bioworld.com/biodrugs E-mail: orders@bioworld.com